PHAARMASIA LTD. is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated |
|---|
| Revenue |
| EBITDA (ex other income) |
| margin % |
| Owners' profit |
| EPS, as reported (₹) |
| ROE % · ROCE % |
| Debt / equity (x) |
| Cash from operations |
| Capex |
| ₹ crore | Q1 FY24 |
|---|---|
| Revenue | 7 |
| Profit before tax | (0) |
| Net profit | (0) |
| EPS (₹) | (0.39) |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 4 Sept 2026 · Phaarmasia responds to BSE query on significant price movement | regulatory legal | medium | — | — |
| 3 Sept 2026 · Phaarmasia 45th AGM notice published in newspapers on September 3, 2026 | compliance | minimal | — | — |
| 3 Sept 2026 · Phaarmasia submits FY26 Annual Report; PAT jumps to Rs 17.57 Cr | compliance | low | — | — |
| 3 Sept 2026 · Phaarmasia 45th AGM on 25 Sep 2026 via video conferencing | board shareholder meetings | low | — | — |
| 31 Aug 2026 · BSE seeks clarification from Phaarmasia on price movement | regulatory legal | medium | — | — |
| 14 Aug 2026 · Phaarmasia reports Q1 FY27 net profit of Rs 33.90 lakh; income at Rs 656.46 lakh | compliance | minimal | — | — |
| 10 Aug 2026 · Phaarmasia board meeting on 13 Aug 2026 to consider Q1 FY27 results | results | low | — | — |
| 16 Jul 2026 · SEBI Regulation 74(5) compliance certificate filed for June 2026 quarter | compliance | minimal | — | — |
| 27 Jun 2026 · Trading window closed from July 1, 2026 until Q1 FY27 results announcement | compliance | minimal | — | — |
| 10 Jun 2026 · The Exchange has sought clarification from Phaarmasia Ltd on June 10, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information .... | regulatory legal | high | — | — |
| Where a broker report shows | This document shows |
|---|
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| EBITDA margin | (2.6) | 17.5 | 156 of 165 | 6% |
| Market cap | 59 | 839 | 144 of 182 | 21% |
| Why |
|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
